贝伐单抗靶向治疗结直肠癌的临床研究进展
被引量:1
摘要
分子靶向治疗已成为结直肠癌治疗的有效策略。最近,血管生成抑制疗法日益成熟,针对血管内皮生长因子(VEGF)的重组人源化单克隆抗体贝伐单抗(bevacizumab,商品名:Avastin,阿瓦斯丁^TM)成为结直肠癌治疗研究的热点。美国食品药品管理局(FDA)于2004年批准贝伐单抗为晚期结直肠癌的一线用药,
出处
《胃肠病学》
2007年第5期305-307,共3页
Chinese Journal of Gastroenterology
参考文献22
-
1Gerber HP,Ferrara N.The role of VEGF in normal and neoplastic hematopoiesis.J Mol Med,2003,81 (1):20-31.
-
2Lee JC,Chow NH,Wang ST,et al.Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients.Eur J Cancer,2000,36 (6):748-753.
-
3Choi HJ,Hyun MS,Jung GJ,et al.Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence.Oncology,1998,55 (6):575-581.
-
4Warren RS,Yuan H,Matli MR,et al.Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.J Clin Invest,1995,95 (4):1789-1797.
-
5de Castro Junior G,Puglisi F,de Azambuja E,et al.Angiogenesis and cancer:A cross-talk between basic science and clinical trials (the "do ut des" paradigm).Crit Rev Oncol Hematol,2006,59 (1):40-50.
-
6Jain RK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy.Science,2005,307 (5706):58-62.
-
7Wang Y,Fei D,Vanderlaan M,et al.Biological activity of bevacizumab,a humanized anti-VEGF antibody in vitro.Angiogenesis,2004,7 (4):335-345.
-
8封宇飞,雷静,傅得兴.血管内皮生长因子抑制剂——贝伐单抗[J].中国药学杂志,2005,40(19):1519-1520. 被引量:10
-
9Kabbinavar F,Hurwitz HI,Fehrenbacher L,et al.Phase Ⅱ,randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.J Clin Oncol,2003,21 (1):60-65.
-
10Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer.N Engl J Med,2004,350 (23):2335-2342.
二级参考文献10
-
1Zondor SD, Medina PJ.Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies [ J ] . Ann Pharmacoth,2004, 38(7-8): 1258.
-
2Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy[ J]. Oncologist, 2004, 9(Suppl 1): 2.
-
3Hsei VC, Novotny WF, Margolin K, et al.Population pharmacokinetic (PK) analysis of bevacizumab(BV) in cancer subjects(abstract)[J].Proc Am Soc Clin Oncol, 2001, 20: 69a.
-
4Gorden MS, Margolin K, Talpaz M, et al.Phase Ⅰ safety and pharmacokintic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer[J]. J Clin Oncol, 2001, 19:843.
-
5FDA, AVASTINTM[DB/OL], http:/www.fda, gov/cder/foi/label/2004/12/1250581bl .pdf, 2004-08-11
-
6Hurwitz H, Fehrenbacher L, Novotny W, et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J] .N Engl J Med ,2004 , 350(23):2335.
-
7Kabbinavar F, Hurwitz HI, Fehrenbacher L, etal, Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer[J]. J Clin Oncol , 2003, 21(1):60.
-
8Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phaseⅡ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [ J ] . J Clin Oncol ,2004, 22(11):2184.
-
9Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias:therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab [ J ]. Clin Cancer Res, 2004, 10 ( 11 ):3577.
-
10Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer[ J ] . N Engl J Me, 2003, 349 (5): 427.
共引文献9
-
1李贞,倪卫杰.视网膜新生血管生物药物治疗研究进展[J].国际眼科杂志,2007,7(4):1119-1123. 被引量:17
-
2苏强,成霄黎,麻文萍.生长因子抑制剂贝伐单抗玻璃体腔注射对眼组织结构的影响[J].中国组织工程研究与临床康复,2008,12(20):3879-3883. 被引量:1
-
3陈日新,逯华.贝伐单抗治疗晚期大肠癌的研究进展[J].现代肿瘤医学,2009,17(1):178-180. 被引量:2
-
4任勇军,杨林,翟昭华.VEGF在原发性肝癌介入治疗中的价值[J].世界华人消化杂志,2010,18(15):1582-1587. 被引量:6
-
5孙影,刘巍,杨方.光动力疗法联合贝伐珠单抗治疗裸鼠U87胶质瘤的实验研究[J].中国激光医学杂志,2011,20(3):149-153. 被引量:1
-
6吴申,周强,周春苗,马莉,谭玉洁,余红岚,蒋红梅.贝伐珠单抗联合化疗治疗晚期肺腺癌[J].中国新药与临床杂志,2015,34(3):221-225. 被引量:2
-
7李雪梅,王纯雁.贝伐单抗联合紫杉醇和奈达铂治疗晚期及复发宫颈癌的疗效观察[J].现代药物与临床,2016,31(2):203-206. 被引量:16
-
8何咏梅.贝伐单抗、紫杉醇和顺铂联合应用治疗晚期宫颈癌的临床效果[J].中国卫生标准管理,2016,7(15):108-109. 被引量:3
-
9袁香坤,孙云川,左晓娜,张永侠,郜蕾,苗珺珺.贝伐单抗治疗放射性脑坏死1例[J].肿瘤学杂志,2016,22(9):774-776. 被引量:1
同被引文献5
-
1陈万灵,欧阳学农.新药贝伐单抗的临床应用进展[J].中国肿瘤,2010,19(8):534-539. 被引量:18
-
2戚川,周彩存.贝伐单抗一线治疗非小细胞肺癌研究进展[J].肿瘤学杂志,2011,17(4):294-297. 被引量:6
-
3毕华,范文红,韩春梅,李响,王兰,丁有学,陶磊,裴德宁,高凯,饶春明.重组人源化兔抗VEGF单克隆抗体质控方法与质量标准研究[J].药物分析杂志,2012,32(6):1054-1058. 被引量:7
-
4朱斌,柳仓生.贝伐单抗在晚期非小细胞肺癌治疗中的应用进展[J].天津医药,2012,40(9):965-968. 被引量:6
-
5范文红,陶磊,李响,丁有学,韩春梅,裴德宁,郭莹,杨靖青,毕华,饶春明,王军志.美妥珠单抗(HcHAb18)质量标准的建立及理化对照品结构确证[J].中国新药杂志,2014,23(20):2360-2365. 被引量:3
-
1韩铭(综述),邓华瑜(审校).曲妥珠单抗在乳腺癌中的耐药机制研究进展[J].中华医学教育探索杂志,2011,10(9):1150-1152.
-
2任文晓,江泽飞,宋三泰.bevacizumab治疗乳腺癌的基础和临床研究[J].国际肿瘤学杂志,2006,33(8):600-602.
-
3曹璐,杨昭志,陈佳艺.乳腺癌放疗联合曲妥珠单抗的心脏毒性与保护研究进展[J].中华放射肿瘤学杂志,2013,22(1):84-86. 被引量:1
-
4赵红,李小龙,崔洁,冯谢敏,宋炜.曲妥珠单抗治疗胃癌的研究进展[J].延安大学学报(医学科学版),2012,10(1):25-27. 被引量:4
-
5流小舟,吴苏稼,施鑫.贝伐单抗在骨肉瘤治疗中的研究进展[J].江苏医药,2012,38(14):1698-1700.
-
6郑铎,吕超,吴玉立,吴硕东.贝伐单抗联合FOLFIRI方案治疗转移性结直肠癌的研究进展[J].肿瘤,2013,33(6):571-574. 被引量:6
-
7黄成兰,陆云海,俞智华.贝伐单抗联合卡培他滨治疗进展期胃癌15例初步观察[J].交通医学,2011,25(5):481-482. 被引量:4
-
8彭建柳,杨丽华.人源化单克隆抗体用于肿瘤分子靶向治疗的研究进展[J].现代医院,2009,9(5):8-11. 被引量:2
-
9易添宝.前列腺癌药物增加糖尿病和心脏病风险[J].心血管病防治知识,2011(1):63-63.
-
10陆志城.厄罗替尼及其有关热点问题[J].中国处方药,2005,4(4):70-72. 被引量:2